News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Bayer AG’s Blood-Thinner Xarelto Matches Warfarin in Irregular-Heartbeat Test
November 1, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
FRANKFURT (Reuters) - A new stroke prevention drug developed by Bayer and Johnson & Johnson proved a safe alternative to the standard treatment, lifting their chances of entering a $12 billion plus market, the German drug company said.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
MORE ON THIS TOPIC
Neuroscience
Epilepsy Biotech Nabs up to $570M in Deal With Italy’s Angelini Plus $140M Fundraising
May 27, 2025
·
1 min read
·
Annalee Armstrong
Gene therapy
Rocket’s Danon Disease Gene Therapy on Hold After Patient Death
May 27, 2025
·
2 min read
·
Tristan Manalac
Funding
Karuna, Naurex Alumni Launch New Biotech
to Modulate Synaptic Plasticity for Neuro Diseases
May 27, 2025
·
3 min read
·
Heather McKenzie
Rare diseases
Prothena Looks at Business Options as Phase III AL Amyloidosis Trial Fails
May 27, 2025
·
2 min read
·
Tristan Manalac
